Molecular Imaging Links Systemic Inflammation with Depression
New data open door to potential diagnostic and treatment options
New research published in the April issue of The Journal of Nuclear Medicine reveals that systemic inflammation causes an increase in depressive symptoms and metabolic changes in the parts of the brain responsible for mood and motivation. With this finding, researchers can begin to test potential treatments for depression for patients that experience symptoms that are related to inflammation in the body or within the brain.
Multiple studies in rodents have shown that inflammation in the body has effects on the brain. This has also been shown in a few human studies—both through measurements of behavioral changes and brain imaging—when subjects were engaged in various computer tasks. The study “Glucose Metabolism in the Insula and Cingulate Is Affected by Systemic Inflammation in Humans,” however, for the first time measured brain activity when subjects were at rest.
“In the study we usedF-18 fluorodeoxyglucose(FDG) positron emission tomography (PET), which can accurately measure glucose metabolism in the brain, to determine which brain regions responded to systemic inflammation. Since the subjects were at rest, the changes we observed in the brain can only attributed to systemic inflammation,” noted Jonas Hannestad, MD, PhD, lead author of the article.
In the study, nine healthy individuals received a double-blind endotoxin (which elicits systemic inflammation and mild depressive symptoms such as fatigue and reduced social interest) and placebo on different days. After administration, F-18 FDG PET was used to measure the differences in the cerebral metabolic rate of glucose in the insula, cingulate and amygdala regions of the brain. Behavior changes were also primarily assessed on the Montgomery-Asberg Depression Rating Scale (MADRS).
A statistical analysis of the results showed that endotoxin administration was associated with a higher normalized glucose metabolism (NMG) in the insula and lower NMG in the cingulate compared to the placebo; there was no significant difference in the NMG in the amygdala. Seven of nine subjects had an increase in NMG in the insula and a decrease in NMG in the cingulate, and all nine subjects had a decrease in NMG in the right anterior cingulate, suggesting that systemic inflammation induces fundamental physiologic changes in regional brain glucose metabolism. In addition, the MADRS increased for each subject after endotoxin administration, whereas no significant change was noted with the placebo.
Most researchers agree that depression is not a homogeneous disease, but rather that there are multiple mechanisms that can lead to similar symptoms. “If we can show that a subtype of depression is caused in part by inflammation,” said Hannestad, “we can test the ability of treatments that reduce inflammation in only patients in whom we believe inflammation plays a role.In the future, I expect that researchers in this field will be able to develop more precise PET measures that can be used to distinguish between, for instance, a person with ‘inflammatory depression’ and a person with another kind of depression. PET could then be used as diagnostic biomarker to separate subtypes of depression and as a therapeutic biomarker to detect the response to treatment.”
Nearly 17 percent of adults experience depression at some point over their lifetime, with 30.4 percent of cases classified as severe, according to the U.S. National Institute of Mental Health. Fifty-seven percent of adults with depression report receiving treatment in the past 12 months, although 37.8 percent receive minimally adequate treatment.
Authors of the article “Glucose Metabolism in the Insula and Cingulate Is Affected by Systemic Inflammation in Humans” include: Jonas Hannestad, Kalyani Subramanyam, Nicole DellaGioia and Brian Pittman, Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut; and Beata Planeta-Wilson, David Weinzimmer and Richard E. Carson, Department of Diagnostic Radiology, Yale School of Medicine, New Haven, Connecticut.
To schedule an interview with the researchers, please contact Susan Martonik at (703) 652-6773 or firstname.lastname@example.org.Current and past issues of The Journal of Nuclear Medicinecan be found online at http://jnm.snmjournals.org.
About SNM—Advancing Molecular Imaging and Therapy
SNM is an international scientific and medical organization dedicated to raising public awareness about what molecular imaging is and how it can help provide patients with the best health care possible. SNM members specialize in molecular imaging, a vital element of today’s medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated.
SNM’s more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snm.org.
Susan Martonik | EurekAlert!